2° GIORNATA BERGAMASCA DI RADIOTERAPIA ONCOLOGICA «OLTRE I CONFINI: L’EVOLUZIONE DELL’ONCOLOGIA NELLA CURA DEL PAZIENTE»

1. 1.Herbst RS, Morgensztern D, Boshoff C.. The biology and management of non-small cell lung cancer.. Nature. 2018;553:446–454.. 2018
   Articolo scientificoNature. 2018;553:446–454.Leggi il paperCerca versione gratuita
2. 2.Hanna NH et al.. Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO–CCO Guidelines.. J Clin Oncol. 2021;39(9):1040–1091.. 2021
   Articolo scientificoJ Clin Oncol. 2021;39(9):1040–1091.Cerca su Google Scholar
3. 3.Reck M, Rodríguez-Abreu D, et al.. Pembrolizumab versus Chemotherapy for PD-L1–Positive NSCLC.. N Engl J Med. 2016;375:1823–1833.. 2016
   Articolo scientificoN Engl J Med. 2016;375:1823–1833.Cerca su Google Scholar
4. 4.Zurita AJ,et al.. Genomic Biomarkers and Genome-Wide Loss-of-Heterozygosity Scores in Metastatic Prostate Cancer Following Progression on Androgen-Targeting Therapies.. JCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195. 2022
   Articolo scientificoJCO Precis Oncol. 2022 Jul;6:e2200195. doi: 10.1200/PO.22.00195Leggi il PDF gratuito
5. 5.de Bono J, et al.. N Engl J Med. 2020 May 28;382(22):2091-2102. doi: 10.1056/NEJMoa1911440. Epub 2020 Apr 28.. 2020
   Articolo scientificoEpub 2020 Apr 28.Cerca su Google Scholar
6. 6.Cancer Genome Atlas Research Network.. The Molecular Taxonomy of Primary Prostate Cancer.. Cell. 2015 Nov 5;163(4):1011-25. doi: 10.1016/j.cell.2015.10.025 4)Shao C, et al. A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations,. 2015
   Articolo scientificoCell. 2015 Nov 5;163(4):1011-25. doi: 10.1016/j.cell.2015.10.025 4)Shao C, et al. A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations,Cerca su Google Scholar
7. 7.Shao C, et al.. A Systematic Review and Meta-Analysis on the Prognostic Value of BRCA Mutations, Homologous Recombination Gene Mutations, and Homologous Recombination Deficiencies in Cancer.. J Oncol. 2022 Jul 20;2022:5830475. doi: 10.1155/2022/5830475. 2022
   Articolo scientificoJ Oncol. 2022 Jul 20;2022:5830475. doi: 10.1155/2022/5830475Leggi il PDF gratuito
8. 8.Dai YH, et al.. A Meta-Analysis and Meta-Regression of the E¿¿icacy, Toxicity, and Quality of Life Outcomes Following Prostate-Specific Membrane Antigen Radioligand Therapy Utilising Lutetium-177 and Actinium-225. Metastatic Prostate Cancer. Eur Urol. 2025 Apr;87(4):398-408. doi: 10.1016/j.eururo.2024.09.020. Epub 2024 Sep 25. 2024
   Articolo scientificoMetastatic Prostate Cancer. Eur Urol. 2025 Apr;87(4):398-408. doi: 10.1016/j.eururo.2024.09.020. Epub 2024 Sep 25Leggi il PDF gratuito
9. 9.Dyrskjøt et al.. Bladder cancer. Nat Rev Dis Primers 2023; 9:58.. 2023
   Articolo scientificoNat Rev Dis Primers 2023; 9:58.Leggi il PDF gratuito
10. 10.Filon M, Schmidt B.. New Treatment Options for Non-Muscle-Invasive Bladder Cancer.. Am Soc Clin Oncol Educ Book 2025;45:e471942.. 2025
    New Treatment Options for Non-Muscle-Invasive Bladder Cancer.
    LibroCerca su Amazon
11. 11.Galsky et al.. Muscle-Invasive Bladder Cancer: A Watershed Moment. Clin Oncol 2025;43:3041-51.. 2025
    Articolo scientificoClin Oncol 2025;43:3041-51.Leggi il paperCerca versione gratuita
12. 12.Powles et al.. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.. N Engl J Med 2024;390:875-88.. 2024
    Articolo scientificoN Engl J Med 2024;390:875-88.Leggi il paperCerca versione gratuita
13. 13.Li et al.. FGFR Inhibition in Urothelial Carcinoma. Eur Urol 2025;87:110-22.. 2025
    Articolo scientificoEur Urol 2025;87:110-22.Leggi il PDF gratuito

I link ai libri possono contenere un codice affiliato Amazon: in qualità di affiliato, ECM Finder potrebbe ricevere una commissione sugli acquisti idonei, senza alcun costo aggiuntivo per te. I link ai paper rimandano alla fonte scientifica (DOI, versione open-access o ricerca accademica).